ArticlePediatric nephrology (Berlin, Germany)2025
Long-term health outcomes of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990-2020.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-Infectious Sequelae Following a Shiga Toxin-ProducingOpen forum infectious diseases · 2026Article
- Phenotypic and Genomic Profiling ofAntibiotics (Basel, Switzerland) · 2026Article
- Biosensing technologies for foodborne pathogen detection and healthcare: principles, emerging materials, and intelligent platforms.Mikrochimica acta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInformation on sequelae of Shiga toxin-producing Escherichia coli (STEC) O157 infection is limited to follow-up of paediatric haemolytic uraemic syndrome (HUS) cases. We investigate recorded long-term health outcomes experienced by individuals exposed to STEC O157 and STEC-HUS up to three decades on.
methodsWe compared acute or new onset of chronic outcomes in individuals ≥ 1 year after STEC O157 or STEC-HUS to unexposed general population comparators between 01/01/1990-01/01/2019. The unexposed were their age- and sex-equivalents (4:1 matching ratio) and assigned the same study entry date. Outcomes were identified in primary and secondary care and categorised as kidney, neurological, cardiac, gastrointestinal, respiratory, or endocrine. Hazard ratios (HRs) and 95% confidence intervals (95% CI) were calculated using Cox regression.
resultsOf 1,245 individuals with STEC O157, 65 developed HUS (5.2%). Individuals with STEC O157 were more likely to experience kidney (adjusted (a)HR: 1.9, 95% CI: 1.1-3.3), gastrointestinal (aHR: 1.7, 95% CI: 1.1-2.5) and respiratory (aHR: 1.4, 95% CI: 1.2-1.6) outcomes compared to the unexposed, on average between 3.4-11 years after exposure. Gastrointestinal (HR: 7.7, 95% CI: 2.6-23), kidney (HR: 5.5, 95% CI: 1.6-19), cardiac (HR: 5.1, 95% CI: 1.1-23) and respiratory (HR: 1.9, 95% CI: 1.1-3.1) outcomes were more common in the STEC-HUS cohort and occurred sooner, on average after 2.7-4.8 years.
conclusionsLong-term complications were nearly twice as likely in the STEC O157 cohort, and as many as eight times more likely following STEC-HUS. We recommend that those exposed to STEC be monitored for at least five years for late-emerging kidney and extrarenal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.